🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07692542
Starting soon Not applicable

Network-Guided Individualized TMS for BPSD in Alzheimer's Disease: A Double-blind Randomized Controlled Trial

NCT07692542 · tracked via the Priya Life Science China tracker
Sponsor
Anhui Medical University
Phase
Not applicable
Started
2026-07-01
Last updated
2026-07-09

Condition(s) studied

Transcranial Magnetic StimulationBehavioral and Psychological Symptoms in Alzheimer's DiseaseIndividualized Navigation

Investigational drug(s) / intervention(s)

transcranial magnetic stimulationtranscranial magnetic stimulation

transcranial magnetic stimulation: Neuronavigated Theta-Burst Transcranial Magnetic Stimulation Other Name:

transcranial magnetic stimulation: Neuronavigated Theta-Burst Transcranial Magnetic Stimulation Other Name:

Study summary

Evaluate the safety and efficacy of personalized network-guided transcranial magnetic stimulation for treating behavioral and psychological symptoms in patients with Alzheimer's disease.

Eligibility

Sex
ALL
Min age
50 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * 1.Diagnosis of Alzheimer's disease according to the 2011 NIA-AA diagnostic criteria. 2.Mini-Mental State Examination (MMSE) score between 10 and 24; 3.Clinical Dementia Rating (CDR) score between 0.5 and 2; 4.Neuropsychiatric Inventory (NPI) score ≥4; 5.Education duration ≥5 years, or ability to complete the required cognitive and neuropsychological assessments; 6.Age ≥50 years and right-handedness; 7.Stable use of anti-dementia medications, including an NMDA receptor antagonist and/or cholinesterase inhibitors, for at least one month before rTMS intervention; 8.The patient and his or her family member or legal representative are able to understand the study procedures and provide written informed consent. Exclusion Criteria: * 1\. Recevied rTMS treatment in the past 3 months. 2. Depression or other psychiatric disorders. 3. History of head injury, stroke, epilepsy or other neurologic disease. 4. Organic brain defects on T1 or T2 images. 5. History of unexplained loss of consciousness. 6. Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, or any implanted medical device that is incompatible with MRI. 7. Family history of medication refractory epilepsy. 8. History of substance abuse within the last 6 months.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Anhui Medical University Hefei Anhui

More Anhui Medical University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07692542 on ClinicalTrials.gov ↗ ← All trials in China